Rice Hall James & Associates LLC Acquires 16,719 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Rice Hall James & Associates LLC grew its holdings in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) by 22.2% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 92,142 shares of the biotechnology company’s stock after buying an additional 16,719 shares during the period. Rice Hall James & Associates LLC owned approximately 0.10% of Rocket Pharmaceuticals worth $1,702,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Janus Henderson Group PLC raised its position in shares of Rocket Pharmaceuticals by 174.3% during the first quarter. Janus Henderson Group PLC now owns 2,606,016 shares of the biotechnology company’s stock worth $70,170,000 after purchasing an additional 1,656,111 shares during the period. Price T Rowe Associates Inc. MD raised its position in shares of Rocket Pharmaceuticals by 11.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,943,160 shares of the biotechnology company’s stock worth $79,290,000 after purchasing an additional 314,086 shares during the period. First Turn Management LLC raised its position in shares of Rocket Pharmaceuticals by 123.6% during the second quarter. First Turn Management LLC now owns 560,989 shares of the biotechnology company’s stock worth $12,078,000 after purchasing an additional 310,119 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Rocket Pharmaceuticals by 75.0% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 301,832 shares of the biotechnology company’s stock worth $8,131,000 after purchasing an additional 129,358 shares during the period. Finally, Renaissance Technologies LLC acquired a new position in shares of Rocket Pharmaceuticals during the second quarter worth approximately $2,144,000. 98.39% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $65.00 price target on shares of Rocket Pharmaceuticals in a research report on Tuesday, August 6th. Needham & Company LLC reissued a “buy” rating and issued a $52.00 price target on shares of Rocket Pharmaceuticals in a research report on Tuesday, September 17th. Canaccord Genuity Group reissued a “buy” rating and issued a $38.00 price target on shares of Rocket Pharmaceuticals in a research report on Monday, September 30th. JPMorgan Chase & Co. upped their price objective on Rocket Pharmaceuticals from $50.00 to $54.00 and gave the company an “overweight” rating in a research note on Tuesday, August 6th. Finally, Scotiabank began coverage on Rocket Pharmaceuticals in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $50.00 price objective for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company. According to MarketBeat, Rocket Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $51.75.

Rocket Pharmaceuticals Stock Up 2.0 %

Shares of NASDAQ RCKT opened at $16.98 on Friday. The business has a 50-day simple moving average of $18.24 and a two-hundred day simple moving average of $20.71. Rocket Pharmaceuticals, Inc. has a 52 week low of $15.98 and a 52 week high of $32.53. The company has a market cap of $1.55 billion, a P/E ratio of -6.09 and a beta of 1.09. The company has a quick ratio of 7.79, a current ratio of 7.79 and a debt-to-equity ratio of 0.05.

Rocket Pharmaceuticals (NASDAQ:RCKT) last released its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.02). During the same quarter in the previous year, the firm earned ($0.82) earnings per share. Research analysts anticipate that Rocket Pharmaceuticals, Inc. will post -2.98 earnings per share for the current fiscal year.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.